development of appropriate clinical dose regimens of individual plasminogen activators such as tissue-type plasminogen activator ( t-pa ) has generally relied primarily on nonpharmacological endpoints such as angiographically documented clot lysis .
C0032144
plasminogen
C0032143
tissue-type plasminogen activator